This article is more than 5 years old. Information may no longer be current.
Corneal endothelium tolerates acute IOP increase after bevacizumab injection
Click Here to Manage Email Alerts
Short-term effects of rapid IOP spikes on corneal endothelium were “tolerable” after intravitreal bevacizumab injection, according to a study.
Researchers prospectively evaluated the effects on corneal endothelium of acute increase in IOP following intravitreal injection of 2.5 mg/0.1 mL Avastin (bevacizumab, Genentech) in 42 patients with central serous chorioretinopathy or diabetic macular edema. Each patient’s contralateral eye, which had no history of intravitreal injection, was used as control.
Mean IOP at baseline before the injection was 11.48 mm Hg. Mean IOP increased to a high of 49.71 mm Hg at 2 minutes after injection and decreased to 14.88 mm Hg at 30 minutes.
“First, IOP highly increased after intravitreal bevacizumab injection, but it recovered to normal range within 30 minutes,” study coauthor Myungwon Lee, MD, told Ocular Surgery News. “I think the acute increase of IOP happened due to acute increase of vitreous volume in limited eyeball space. Second, the acute increase of IOP did not affect corneal endothelial cells.”
There was a significant increase (P = .03) in coefficient of variation (CV) of the corneal endothelium, which Lee attributed as follows: “Although CV temporarily changed in the high IOP period, I think CV was affected by mechanical stretching by the acute increase of IOP.”
Cell density, hexagonality of the corneal endothelium and central corneal thickness did not significantly increase or decrease, and there were no complications or inflammation at 1 week follow-up in any of the treated eyes. – by Robert Linnehan
Disclosures: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts